REG - e-Therapeutics plc - Result of Annual General Meeting

E-TherapeuticsAnnouncement

20/07/2022 10:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220720:nRST1423Ta&default-theme=true

RNS Number : 1423T  e-Therapeutics plc  20 July 2022

 

e-therapeutics plc

("e-therapeutics" or the "Company")

 

Result of Annual General Meeting

 

 

London, UK, 20 July 2022 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a
specialist in computational drug discovery with a focus on developing RNA
interference ("RNAi") announces that at its Annual General Meeting held on 19
July 2022, all resolutions, as set out in the Notice of Meeting, were duly
passed.

 

The votes were as follows:

 

                        Votes For    %     Votes       %      Abstentions  Resolution Result

                                           Against

 Ordinary Resolution 1  305,293,944  99.9  5,546       0.002  2,351,340    Passed
 Ordinary Resolution 2  305,293,944  99.9  5,546       0.002  2,351,340    Passed
 Ordinary Resolution 3  307,642,963  99.9  7,867       0.003  0            Passed
 Ordinary Resolution 4  307,637,284  99.9  5,546       0.002  8,000        Passed
 Ordinary Resolution 5  307,645,284  99.9  5,546       0.002  0            Passed
 Special Resolution 6   291,094,090  95.3  14,197,400  4.650  2,359,340    Passed

 

 

Enquiries:

 e-therapeutics plc
 Ali Mortazavi,                                                                        Tel: +44 (0)20 4551 8888
 CEO

                                                                                     www.etherapeutics.co.uk
 James Chandler, VP IR & Strategic Communications

      SP Angel Corporate Finance LLP

                                                                                       Tel: +44(0)20 3470 0470
 Nominated Adviser and Broker
 Matthew Johnson/Caroline Rowe (Corporate Finance)
 Vadim Alexandre/Rob Rees (Corporate Broking)

 
 
About e-therapeutics plc

 

e-therapeutics plc is a UK-based company integrating computational power and
biology to accelerate the discovery of life-transforming medicines. The
Company has developed and validated a powerful, disease and modality agnostic
computational approach to drug discovery, leveraging its industry-leading
expertise in network biology to fully capture and interrogate human disease
complexity.

 

The Company's multi-disciplinary team builds computational models of
biological functions to transform the search for new medicines, interventions,
mechanisms and genetic support. Its biology-led in silico laboratory enables
rapid hypothesis generation and phenotypic screening of millions of compounds
leading to 100-1000x higher hit rates in the wet lab and successful mode of
action elucidation. Novel targets can also be identified, prioritised and
assessed. Harnessing internal target gene discoveries, e- therapeutics is
currently building an in-house pipeline of RNAi based medicines, using its
proprietary GalNAc-siRNA technology.

 

e-therapeutics has deployed and validated its disease-agnostic computational
drug discovery platform both in house and with partners, including Novo
Nordisk, Galapagos NV, iTeos and a US-based, top 5 pharmaceutical company.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGUROKRUBUBURR